The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Innovative Biologics and Biosimilars Market Research Report 2025
Synopsis
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
Global Innovative Biologics and Biosimilars market is projected to reach US$ 674510 million in 2029, increasing from US$ 468270 million in 2022, with the CAGR of 8.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Innovative Biologics and Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Innovative Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Innovative Biologics and Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
Global Innovative Biologics and Biosimilars market is projected to reach US$ 674510 million in 2029, increasing from US$ 468270 million in 2022, with the CAGR of 8.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Innovative Biologics and Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Innovative Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory
Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Innovative Biologics and Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Innovative Biologics and Biosimilars Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Innovative Biologics and Biosimilars Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Innovative Biologics and Biosimilars Market Perspective (2018-2029)
2.2 Innovative Biologics and Biosimilars Growth Trends by Region
2.2.1 Global Innovative Biologics and Biosimilars Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Innovative Biologics and Biosimilars Historic Market Size by Region (2018-2023)
2.2.3 Innovative Biologics and Biosimilars Forecasted Market Size by Region (2024-2029)
2.3 Innovative Biologics and Biosimilars Market Dynamics
2.3.1 Innovative Biologics and Biosimilars Industry Trends
2.3.2 Innovative Biologics and Biosimilars Market Drivers
2.3.3 Innovative Biologics and Biosimilars Market Challenges
2.3.4 Innovative Biologics and Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Innovative Biologics and Biosimilars Players by Revenue
3.1.1 Global Top Innovative Biologics and Biosimilars Players by Revenue (2018-2023)
3.1.2 Global Innovative Biologics and Biosimilars Revenue Market Share by Players (2018-2023)
3.2 Global Innovative Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Innovative Biologics and Biosimilars Revenue
3.4 Global Innovative Biologics and Biosimilars Market Concentration Ratio
3.4.1 Global Innovative Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Innovative Biologics and Biosimilars Revenue in 2022
3.5 Innovative Biologics and Biosimilars Key Players Head office and Area Served
3.6 Key Players Innovative Biologics and Biosimilars Product Solution and Service
3.7 Date of Enter into Innovative Biologics and Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Innovative Biologics and Biosimilars Breakdown Data by Type
4.1 Global Innovative Biologics and Biosimilars Historic Market Size by Type (2018-2023)
4.2 Global Innovative Biologics and Biosimilars Forecasted Market Size by Type (2024-2029)
5 Innovative Biologics and Biosimilars Breakdown Data by Application
5.1 Global Innovative Biologics and Biosimilars Historic Market Size by Application (2018-2023)
5.2 Global Innovative Biologics and Biosimilars Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Innovative Biologics and Biosimilars Market Size (2018-2029)
6.2 North America Innovative Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Innovative Biologics and Biosimilars Market Size by Country (2018-2023)
6.4 North America Innovative Biologics and Biosimilars Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Innovative Biologics and Biosimilars Market Size (2018-2029)
7.2 Europe Innovative Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Innovative Biologics and Biosimilars Market Size by Country (2018-2023)
7.4 Europe Innovative Biologics and Biosimilars Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Innovative Biologics and Biosimilars Market Size (2018-2029)
8.2 Asia-Pacific Innovative Biologics and Biosimilars Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Innovative Biologics and Biosimilars Market Size by Region (2018-2023)
8.4 Asia-Pacific Innovative Biologics and Biosimilars Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Innovative Biologics and Biosimilars Market Size (2018-2029)
9.2 Latin America Innovative Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Innovative Biologics and Biosimilars Market Size by Country (2018-2023)
9.4 Latin America Innovative Biologics and Biosimilars Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Innovative Biologics and Biosimilars Market Size (2018-2029)
10.2 Middle East & Africa Innovative Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Innovative Biologics and Biosimilars Market Size by Country (2018-2023)
10.4 Middle East & Africa Innovative Biologics and Biosimilars Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Innovative Biologics and Biosimilars Introduction
11.1.4 Roche Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Innovative Biologics and Biosimilars Introduction
11.2.4 Amgen Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Innovative Biologics and Biosimilars Introduction
11.3.4 AbbVie Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Innovative Biologics and Biosimilars Introduction
11.4.4 Sanofi Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Innovative Biologics and Biosimilars Introduction
11.5.4 Johnson & Johnson Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Innovative Biologics and Biosimilars Introduction
11.6.4 Pfizer Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Detail
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Innovative Biologics and Biosimilars Introduction
11.7.4 Novo Nordisk Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Detail
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Innovative Biologics and Biosimilars Introduction
11.8.4 Eli Lilly Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Innovative Biologics and Biosimilars Introduction
11.9.4 Novartis Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Innovative Biologics and Biosimilars Introduction
11.10.4 Merck Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.10.5 Merck Recent Development
11.11 Biogen
11.11.1 Biogen Company Detail
11.11.2 Biogen Business Overview
11.11.3 Biogen Innovative Biologics and Biosimilars Introduction
11.11.4 Biogen Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.11.5 Biogen Recent Development
11.12 Celltrion
11.12.1 Celltrion Company Detail
11.12.2 Celltrion Business Overview
11.12.3 Celltrion Innovative Biologics and Biosimilars Introduction
11.12.4 Celltrion Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.12.5 Celltrion Recent Development
11.13 Sobi
11.13.1 Sobi Company Detail
11.13.2 Sobi Business Overview
11.13.3 Sobi Innovative Biologics and Biosimilars Introduction
11.13.4 Sobi Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.13.5 Sobi Recent Development
11.14 3SBIO
11.14.1 3SBIO Company Detail
11.14.2 3SBIO Business Overview
11.14.3 3SBIO Innovative Biologics and Biosimilars Introduction
11.14.4 3SBIO Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.14.5 3SBIO Recent Development
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Detail
11.15.2 Changchun High Tech Business Overview
11.15.3 Changchun High Tech Innovative Biologics and Biosimilars Introduction
11.15.4 Changchun High Tech Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.15.5 Changchun High Tech Recent Development
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Detail
11.16.2 Kanghong Pharma Business Overview
11.16.3 Kanghong Pharma Innovative Biologics and Biosimilars Introduction
11.16.4 Kanghong Pharma Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.16.5 Kanghong Pharma Recent Development
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Detail
11.17.2 Innovent Biologics Business Overview
11.17.3 Innovent Biologics Innovative Biologics and Biosimilars Introduction
11.17.4 Innovent Biologics Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.17.5 Innovent Biologics Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Detail
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Innovative Biologics and Biosimilars Introduction
11.18.4 Gan&Lee Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Detail
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Innovative Biologics and Biosimilars Introduction
11.19.4 Tonghua Dongbao Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Detail
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Innovative Biologics and Biosimilars Introduction
11.20.4 United Laboratory Revenue in Innovative Biologics and Biosimilars Business (2018-2023)
11.20.5 United Laboratory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
